Inhibition of omeprazole induced hypergastrinaemia by SMS 201-995, a long acting somatostatin analogue in man
- PMID: 8406151
- PMCID: PMC1375451
- DOI: 10.1136/gut.34.9.1186
Inhibition of omeprazole induced hypergastrinaemia by SMS 201-995, a long acting somatostatin analogue in man
Abstract
Whether the long acting somatostatin analogue SMS 201-995 (octreotide, Sandostatin) could inhibit the basal and meal stimulated hypergastrinaemia and hyperpepsinogenaemia induced by omeprazole was investigated. Eight healthy subjects were randomised to receive five day courses of SMS 201-995 (25 micrograms subcutaneously three times daily), omeprazole (40 mg once a day), a combination of both drugs, or placebo. Basal and meal stimulated serum gastrin and basal serum pepsinogen A and C values were measured the day before treatment, on day five of treatment, and the day after each course of treatment. Omeprazole caused significant increases in basal and meal stimulated peak and integrated serum gastrin values and pepsinogen A and C levels, which were still significantly raised the day after stopping omeprazole treatment. Giving SMS 201-995 with omeprazole significantly reduced any omeprazole induced increases in basal and meal stimulated peak and integrated serum gastrin levels; serum pepsinogen A and C values were significantly inhibited too. Serum gastrin values during combined therapy were not significantly different from those during placebo treatment, whereas pepsinogen A and C levels were still significantly raised. On the day after stopping combined therapy, basal and meal stimulated peak and integrated serum gastrin and serum pepsinogen C (but not pepsinogen A) levels were not significantly different from values obtained on the day after stopping omeprazole alone. SMS 201-995 without omeprazole significantly inhibited basal and meal stimulated peak and integrated serum gastrin levels. Pepsinogen A was also significantly inhibited by SMS 210-995, but the reduction in pepsinogen C failed to reach statistical significance. In conclusion, SMS 201-995 prevents basal and meal stimulated increases in serum gastrin during omeprazole therapy. This finding may have clinical importance in the few patients who have pronounced hypergastrinaemia because of profound long acting acid inhibition.
Similar articles
-
Effect of enprostil on serum gastrin and pepsinogen A and C levels in patients on long-term treatment with omeprazole.Aliment Pharmacol Ther. 1994 Apr;8(2):221-7. doi: 10.1111/j.1365-2036.1994.tb00282.x. Aliment Pharmacol Ther. 1994. PMID: 8038355
-
Effect of synthetic prostaglandin E2 analog enprostil on omeprazole-induced hypergastrinemia and hyperpepsinogenemia.Dig Dis Sci. 1994 Mar;39(3):609-16. doi: 10.1007/BF02088350. Dig Dis Sci. 1994. PMID: 8131700 Clinical Trial.
-
Weekend treatment with 20 and 40 mg omeprazole: effect on intragastric pH, fasting and postprandial serum gastrin, and serum pepsinogens.Gut. 1991 Sep;32(9):977-82. doi: 10.1136/gut.32.9.977. Gut. 1991. PMID: 1916501 Free PMC article. Clinical Trial.
-
Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.J Physiol Pharmacol. 1994 Dec;45(4 Suppl 1):3-66. J Physiol Pharmacol. 1994. PMID: 7787215 Review.
-
Safety profile of omeprazole. Adverse events with short-term treatment.Digestion. 1989;44 Suppl 1:68-76. doi: 10.1159/000200106. Digestion. 1989. PMID: 2691312 Review.
Cited by
-
Antisecretory and ulcer healing effects of S-0509, a novel CCK-B/gastrin receptor antagonist, in rats.Dig Dis Sci. 1999 May;44(5):879-88. doi: 10.1023/a:1026631808011. Dig Dis Sci. 1999. PMID: 10235591
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources